1. Effects of Curcumin Combined With the 5-alpha Reductase Inhibitor Dutasteride on LNCaP Prostate Cancer Cells
- Author
-
Yan Lu, Kazutaka Saito, Hisamitsu Ide, Gaku Arai, Akiyoshi Osaka, Hiroshi Okada, Shigeo Horie, Kazunori Fukuda, Ayano Takei, and Akinori Nakayama
- Subjects
Male ,Cancer Research ,Curcumin ,medicine.drug_class ,urologic and male genital diseases ,General Biochemistry, Genetics and Molecular Biology ,chemistry.chemical_compound ,5 Alpha-Reductase Inhibitor ,Prostate cancer ,5-alpha Reductase Inhibitors ,Tandem Mass Spectrometry ,Cell Line, Tumor ,LNCaP ,medicine ,Humans ,Testosterone ,Pharmacology ,Prostatic Neoplasms ,Dihydrotestosterone ,Dutasteride ,medicine.disease ,Androgen ,chemistry ,Azasteroids ,Cancer research ,Chromatography, Liquid ,Research Article ,medicine.drug - Abstract
Background/aim Curcumin is a natural compound of turmeric, which inhibits prostate cancer cell proliferation. This study examined whether treatment of LNCaP prostate cancer cells with the combination of curcumin and dutasteride, a 5-alpha reductase inhibitor, affect proliferation and the amount of testosterone and dihydrotestosterone. Materials and methods LNCaP Cells were incubated with curcumin or the combination of curcumin and dutasteride and cell proliferation was measured at 72 h. LC-MS/MS was used to determine testosterone and dihydrotestosterone concentrations in prostate cancer cells. Results Curcumin combined with dutasteride suppressed proliferation and affected apoptosis of LNCaP cells. The combination of curcumin and dutasteride also reduced the amount of testosterone and dihydrotestosterone in LNCaP cells. The secretion of prostate-specific antigen was inhibited by the combination treatment in a dose-dependent manner. Conclusion Treatment with the combination of curcumin and dutasteride may interfere with the intra-tumoral androgen activity.
- Published
- 2021
- Full Text
- View/download PDF